Sign in

Private company

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is an American biological products company based in San Diego, founded in 1989.1

Last updated Oct 21, 2026.

Overview

1989Founded1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSan Diego1
  • Websitelajollapharmaceutical.com
  • Incorporated inDE4
  • Business address201 Jones Road, Suite 400, Waltham, Ma 024514
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation3
  • LEI529900H2JU56H90RYN443
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered address4550 Towne Centre Court, 92121 San Diego, United States3
  • Registered withSecretary of State, C34699453

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

28.8%Operating margin5
26.0%Net margin5
126.6%Revenue growth, 20215
$28.2MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development7¢$5.0M
  • Selling, general and admin47¢$35.4M
  • Other costs21¢$15.6M
  • Income tax0¢$49.0K
  • Profit26¢$19.7M

Out of $75.7M in revenue.5

Where each dollar of operating cash went, fiscal 2021

  • Capital spending0¢$9.0K
  • Share buybacks12¢$3.4M
  • Kept or used elsewhere88¢$24.9M

Out of $28.2M of cash from operations.5

Financial statements

Revenue67895$75.7M in 2021+7064% since 2015
0$20.0M$40.0M$60.0M$80.0M2015: $1.1M$1.1M20152016: $616.0K$616.0K2016−42%2017: $0$020172018: $10.1M$10.1M20182019: $23.1M$23.1M2019+128%2020: $33.4M$33.4M2020+45%2021: $75.7M$75.7M2021+127%
Operating income67895$21.8M in 2021
-$150.0M-$100.0M-$50.0M0$50.0M2015: -$42.0M-$42.0M20152016: -$78.4M-$78.4M2016+87%2017: -$115.4M-$115.4M2017+47%2018: -$57.9M-$57.9M2018−50%2019: -$109.8M-$109.8M2019+90%2020: -$35.8M-$35.8M2020−67%2021: $21.8M$21.8M2021
Net income67895$19.7M in 2021
-$150.0M-$100.0M-$50.0M0$50.0M2015: -$41.9M-$41.9M20152016: -$78.2M-$78.2M2016+87%2017: -$114.8M-$114.8M2017+47%2018: -$62.1M-$62.1M2018−46%2019: -$116.5M-$116.5M2019+88%2020: -$39.4M-$39.4M2020−66%2021: $19.7M$19.7M2021
Fiscal year2015201620172018201920202021
Revenue$1.1M6$616.0K7$07$10.1M8$23.1M9$33.4M5$75.7M5
Cost of revenue$07$07$1.1M8$2.4M9$7.8M9
Research and development$29.1M6$62.3M7$84.6M7$43.3M8$85.3M9$23.0M5$5.0M5
Selling, general and admin$16.7M7$30.9M7$23.6M8$45.1M9$38.4M5$35.4M5
Operating expenses$53.9M5
Operating income-$42.0M6-$78.4M7-$115.4M7-$57.9M8-$109.8M9-$35.8M5$21.8M5
Interest$07$07$7.3M7
Income before tax$19.7M5
Income tax$06$07$07$012$012$05$49.0K5
Net income-$41.9M6-$78.2M7-$114.8M7-$62.1M8-$116.5M9-$39.4M5$19.7M5
Earnings per share-$1.445$0.725
Earnings per share (diluted)-$1.445$0.585
Shares (weighted, basic)27.4M shares5
Shares (weighted, diluted)34.2M shares5

Compare La Jolla Pharmaceutical Company with another company

Corporate structure

La Jolla Pharmaceutical Company is part of a group headed by Innoviva, Inc.. 18 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of La Jolla Pharmaceutical Company

  • Innoviva, Inc. Brisbane, California, United States
    • La Jolla Pharmaceutical Company San Diego, California, United States
    • Advanced Medicine East, Inc Subsidiary · Delaware, United States
    • Entasis Therapeutics (Ireland) Limited Subsidiary · Ireland
    • Entasis Therapeutics Holdings Inc. Subsidiary · Delaware, United States
    • Entasis Therapeutics Inc. Subsidiary · Delaware, United States
    • Innoviva Royalty Sub LLC Subsidiary · Delaware, United States
    • Innoviva Specialty Therapeutics Holdings LLC Subsidiary · Delaware, United States
    • Innoviva Specialty Therapeutics Inc. Subsidiary · Delaware, United States
    • Innoviva Strategic Opportunities LLC Subsidiary · Delaware, United States
    • Innoviva Strategic Partners LLC Subsidiary · Delaware, United States
    • Innoviva TRC Holdings LLC Subsidiary · Delaware, United States
    • ISP Fund LP Subsidiary · Delaware, United States
    • ISTx, LLC Subsidiary · Delaware, United States
    • La Jolla Pharma, LLC Subsidiary · Delaware, United States
    • La Jolla Pharmaceutical Holdings, LLC Subsidiary · Delaware, United States
    • Nortiva Bio, Inc. Subsidiary · Delaware, United States
    • Tetraphase Pharmaceuticals, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What La Jolla Pharmaceutical Company reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$831.0K5 Dec 31, 2021$1.4M5 Dec 31, 2020−38.5%
Accumulated depreciation$718.0K5 Dec 31, 2021$1.1M5 Dec 31, 2020−36.9%
Property and equipment, net$113.0K5 Dec 31, 2021$215.0K5 Dec 31, 2020−47.4%
Operating-lease assets (leased space)$318.0K5 Dec 31, 2021$536.0K5 Dec 31, 2020−40.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$46.7M5 Dec 31, 2021$21.2M5 Dec 31, 2020+119.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$20.1M5 Dec 31, 2021$20.1M5 Dec 31, 20200%
Intangible assets, net (excluding goodwill)$13.3M5 Dec 31, 2021$14.9M5 Dec 31, 2020−10.4%
Finite-lived intangibles, gross$15.5M5 Dec 31, 2021$15.5M5 Dec 31, 20200%
Accumulated amortization$2.2M5 Dec 31, 2021$647.0K5 Dec 31, 2020+239.9%
Finite-lived intangibles, net$13.3M5 Dec 31, 2021$14.9M5 Dec 31, 2020−10.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$6.3M5 Dec 31, 2021$6.0M5 Dec 31, 2020+4.5%
Raw materials$802.0K5 Dec 31, 2021$802.0K5 Dec 31, 20200%
Work in process$4.5M5 Dec 31, 2021$3.2M5 Dec 31, 2020+40.1%
Finished goods$978.0K5 Dec 31, 2021$2.0M5 Dec 31, 2020−51.1%

Leadership

Who has led La Jolla Pharmaceutical Company, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven B. Engle2006
  2. Deirdre Gillespie2006–2011
  3. George F. Tidmarsh2012–2019

Chair

  1. Steven B. Engle2006

President

  1. Deirdre Gillespie2007–2011
  2. George F. Tidmarsh2012–2019

Chief financial officer

  1. Niv Edward Caviar2007–2009
  2. Gail A. Sloan2010–2011
  3. Dennis Mulroy2015–2020
  4. Michael S. Hearne2020–2022
  5. Kevin C. Tang2020–2022

Chief operating officer

  1. Jennifer Carver2017–2019
19901995200020052010201520202025
Board members and other officers (29)

Timeline

  1. Aug 22, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer50
  2. Jul 11, 20228-K Entered a material agreement; Other events51
  3. Feb 16, 20228-K Other events52
  4. Nov 18, 20218-K Other events53
  5. Jan 31, 2012New chief executive George F. Tidmarsh becomes CEO14
  6. Mar 16, 2006New chief executive Deirdre Gillespie becomes CEO16
  7. Feb 10, 2006New chief executive Steven B. Engle becomes CEO15
  8. 1989Founded Founded1

Filings

86 filings to the SEC since October 2021: 2 annual reports, 3 quarterly reports, 5 major events, 53 insider forms, 7 large holders, 16 other. The latest 20:

  1. Feb 14, 2023SC 13G/A LA JOLLA PHARMACEUTICAL COMPANY EDGAR
  2. Sep 1, 202215-12G FORM 15 EDGAR
  3. Aug 29, 2022SC 13D/A EDGAR
  4. Aug 29, 2022SC 13D EDGAR
  5. Aug 24, 2022SC 13D/A AMENDMENT NO. 19 EDGAR
  6. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  7. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  8. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  9. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  10. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  11. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  12. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  13. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  14. Aug 24, 20224 FORM 4 SUBMISSION EDGAR
  15. Aug 23, 2022S-8 POS S-8 POS 333-227819 EDGAR
  16. Aug 23, 2022S-8 POS S-8 POS 333-214722 EDGAR
  17. Aug 23, 2022S-8 POS S-8 POS 333-207212 EDGAR
  18. Aug 23, 2022S-8 POS S-8 POS 333-221197 EDGAR
  19. Aug 23, 2022S-8 POS S-8 POS 333-193016 EDGAR
  20. Aug 22, 202225-NSE EDGAR

The 86 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 4 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 6, 2021RAMSAY DAVID ADirectorBuy10,000$3.82$38.2KForm 4
Dec 3, 2021RAMSAY DAVID ADirectorBuy4,399$3.66$16.1KForm 4
Dec 2, 2021RAMSAY DAVID ADirectorBuy10,101$3.73$37.7KForm 4
Dec 1, 2021TANG CAPITAL PARTNERS LP10% ownerSale177,545$3.74$663.4KForm 4
Nov 30, 2021TANG CAPITAL PARTNERS LP10% ownerSale70,342$3.95$277.9KForm 4
Nov 29, 2021TANG CAPITAL PARTNERS LP10% ownerSale193,403$4.10$793.0KForm 4
Nov 17, 2021RAMSAY DAVID ADirectorBuy7,500$4.23$31.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How La Jolla Pharmaceutical Company is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLA JOLLA PHARMACEUTICAL CO2
  • CIK0000920465
  • Employer ID (EIN)33-03612852
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • Business address201 Jones Road, Suite 400, Waltham, MA 024512
  • Phone617-715-36002
  • Shares outstanding24,936,883 as of Aug 1, 202211
  • Public float$73.3M as of Jun 30, 202157
  • On EDGAR sinceFeb 6, 19962
  • Filings1,496 in all: 4 (595), 8-K (298), SC 13G/A (94), 10-Q (80), 5 (47), SC 13D/A (36), SC 13G (35), 3 (34)2
    All 61 form types

    DEF 14A (25), 10-K (21), S-8 (19), 4/A (15), 424B5 (14), S-3 (13), UPLOAD (13), CORRESP (11), S-8 POS (10), DEFA14A (9), EFFECT (9), PRE 14A (9), 8-A12G/A (8), SC 13D (8), 10-K/A (7), 424B3 (7), 425 (7), NT 10-Q (6), S-3/A (6), 10-K405 (5), 424B2 (4), ARS (4), SC TO-C (4), 8-K/A (3), NT 10-K (3), SC TO-T/A (3), 25-NSE (2), CT ORDER (2), D (2), PRER14A (2), REGDEX (2), SC 14D9/A (2), SC TO-T (2), 10-K405/A (1), 10-Q/A (1), 15-12G (1), 3/A (1), 424B1 (1), 8-A12B (1), 8-A12B/A (1), 8-A12G (1), 8-K12B (1), CERTNAS (1), DEF 14C (1), DEFR14A (1), POS AM (1), PRE 14C (1), S-1 (1), S-3MEF (1), S-4 (1), S-4/A (1), SC 14D9 (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 9, 2022
    Quarterly report (10-Q) Aug 15, 2022
    Proxy statement (DEF 14A) Jun 4, 2021
    Latest 8-K (8-K) Aug 22, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
    SEC EDGAROther events
  54. 54
  55. 55
  56. 56
  57. 57